5AM Venture Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

5AM Venture Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.24M	Hold	3,947,913	–	–	2.56%	13
2025 Q4	$5.33M	Buy	3,947,913 +3,457,913	+706%	+$5.03M	1.68%	19
2025 Q3	$740K	Hold	490,000	–	–	0.27%	24
2025 Q2	$568K	Hold	490,000	–	–	0.22%	28
2025 Q1	$779K	Hold	490,000	–	–	0.29%	30
2024 Q4	$1.48M	Hold	490,000	–	–	0.35%	31
2024 Q3	$1.8M	Hold	490,000	–	–	0.37%	27
2024 Q2	$2M	Hold	490,000	–	–	0.45%	26
2024 Q1	$7.72M	Hold	490,000	–	–	1.73%	18
2023 Q4	$7.42M	Hold	490,000	–	–	1.97%	18
2023 Q3	$9.83M	Hold	490,000	–	–	2.83%	10
2023 Q2	$13.8M	Buy	+490,000	New	+$11.8M	3.44%	8

Other funds holding ZNTL

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

5AM Venture Management's ZNTL Position: Q1 2026 in Review

5AM Venture Management held its Zentalis Pharmaceuticals (ZNTL) position steady in Q1 2026 at 3,947,913 shares worth $9.24M. The position accounts for 2.56% of the portfolio, ranked #13.

5AM Venture Management first reported a position in ZNTL in Q2 2023 and has held it in 12 quarters since. The position peaked at $13.8M in Q2 2023. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

5AM Venture Management held 3,947,913 shares of Zentalis Pharmaceuticals worth $9.24M as of Q1 2026.
5AM Venture Management left its Zentalis Pharmaceuticals share count unchanged in Q1 2026.
Zentalis Pharmaceuticals made up 2.56% of 5AM Venture Management's portfolio in Q1 2026, its #13 holding.
5AM Venture Management first reported a position in Zentalis Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
5AM Venture Management's Zentalis Pharmaceuticals position peaked at $13.8M in Q2 2023.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on 5AM Venture Management's 13F filing for Q1 2026, filed 15 May 2026.